Avraham Pharmaceuticals ^Companies

Avraham Pharmaceuticals is a privately held pharmaceutical company that focuses on developing innovative products for the treatment and prevention of neurodegenerative disorders. Founded in 2010, the company has successfully raised $9 million to conduct a Phase II proof-of-concept efficacy trial in patients with Alzheimer's disease. Their lead product candidate, ladostigil, shows promising potential in addressing the needs of patients suffering from neurodegenerative disorders. Avraham Pharmaceuticals aims to make a significant impact in the field of neurodegenerative disease treatment and improve the lives of patients worldwide.